Trial · NCT03180957

Repurposing Anti-TNF for Treating Dupuytren's Disease

NCT03180957, Phase 2, Completed, University of Oxford; results first posted 2024-06-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Repurposing Anti-TNF for Treating Dupuytren's Disease. Trials, record NCT03180957. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03180957

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Repurposing Anti-TNF for Treating Dupuytren's Disease
NCT number: NCT03180957
Status: Completed
Phases: Phase 2
Enrollment: 140 participants, actual
Lead sponsor: University of Oxford
Conditions: Dupuytren's Disease
Interventions: Adalimumab, Saline
First posted: 2017-06-08
Last updated: 2024-06-28
Other registries' IDs: eudract:2015-001780-40, isrctn:ISRCTN27786905
Results first posted: 2024-06-28

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Early Disease: Nodule Hardness at 12 Months	12 months	Tonometry - A hardness score in arbitrary units with 0 being the lowest hardness and 100 being the greatest hardness units on a scale.
Secondary	Early Disease: Nodule Size	12 months	Measured in mm\^2 where 0 is the smallest and 50 is the largest unit on a scale
Secondary	Early Disease: Grip Strength	12 months	Jamar meter
Secondary	Early Disease: Extension Deficit of Affected Joint	12 months	Overall passive extension deficit of joint affected by treated nodule (degrees)
Secondary	Early Disease: Patient Reported Outcomes	12 months	Michigan Hand Questionnaire - overall hand function with 0 as the lowest ability and 100 best possible ability units on a scale.
Other	Early Disease: Analysis of Resource Use Data	18 months	Patient completed questionnaire about health \& social care and financial costs of Dupuytren's disease

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Early Disease: Nodule Hardness at 12 Months	12 months		Durometer Arbitrary Units (AU)	MEAN
SECONDARY	Early Disease: Nodule Size	12 months		mm^2	MEAN
SECONDARY	Early Disease: Grip Strength	12 months		kg	MEAN
SECONDARY	Early Disease: Extension Deficit of Affected Joint	12 months	baseline were mean imputed. 12 Months: Adalimumab n=63, Saline n=65	degrees	MEAN
SECONDARY	Early Disease: Patient Reported Outcomes	12 months		score on a scale	MEAN
OTHER_PRE_SPECIFIED	Early Disease: Analysis of Resource Use Data	18 months

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Early Disease: Nodule Hardness at 12 Months	Anti-TNF		58.1	Standard Deviation 11.8	Durometer Arbitrary Units (AU)
Early Disease: Nodule Hardness at 12 Months	Placebo		61.2	Standard Deviation 9.8	Durometer Arbitrary Units (AU)
Early Disease: Nodule Size	Anti-TNF		21.8	Standard Deviation 18.7	mm^2
Early Disease: Nodule Size	Placebo		35.9	Standard Deviation 28.9	mm^2
Early Disease: Grip Strength	Anti-TNF		34.5	Standard Deviation 10.7	kg
Early Disease: Grip Strength	Placebo		38.3	Standard Deviation 11.9	kg
Early Disease: Extension Deficit of Affected Joint	Anti-TNF	Overall passive extension deficit of joint affected by treatment nodule	3.3	Standard Deviation 10.2	degrees
Early Disease: Extension Deficit of Affected Joint	Placebo	Overall passive extension deficit of joint affected by treatment nodule	5.0	Standard Deviation 12.8	degrees
Early Disease: Extension Deficit of Affected Joint	Anti-TNF	MCP:passive extension deficit of joint affected by treated nodule	0.0	Standard Deviation 0.0	degrees
Early Disease: Extension Deficit of Affected Joint	Placebo	MCP:passive extension deficit of joint affected by treated nodule	1.4	Standard Deviation 5.7	degrees

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Anti-TNF	70
Overall Study	STARTED	Placebo	70
Overall Study	COMPLETED	Anti-TNF	59
Overall Study	COMPLETED	Placebo	54
Overall Study	NOT COMPLETED	Anti-TNF	11
Overall Study	NOT COMPLETED	Placebo	16

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Adverse Events	Skin and subcutaneous tissue disorders	Anti-TNF	6	70	6
other	Adverse Events	Skin and subcutaneous tissue disorders	Placebo	4	70	4
other	Adverse event	Skin and subcutaneous tissue disorders	Anti-TNF	3	70	3
other	Adverse event	Skin and subcutaneous tissue disorders	Placebo	5	70	5
serious	Pericarditis	Cardiac disorders	Anti-TNF	0	70	0
serious	Pericarditis	Cardiac disorders	Placebo	1	70	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Anti-TNF	0	70
Total, all-cause mortality	Placebo	0	70
Total, other adverse events	Anti-TNF	9	70
Total, other adverse events	Placebo	9	70
Total, serious adverse events	Anti-TNF	0	70
Total, serious adverse events	Placebo	1	70

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29983350	RESULT	PubMed
35949922	RESULT	PubMed
36378072	RESULT	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Anti-TNF vs Placebo: deaths from any cause	Trial comparisons
Anti-TNF vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03180957

GET https://conductscience.org/api/trials/v1/NCT03180957/registered

API reference For AI assistants